Theratechnologies Inc. (THTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for THTX in the last 30 days. The most recent was published Nov 14, 2025.
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.SCHEDULE 13G/A - Theratechnologies Inc. (0001512717) (Subject)
- SECSEC Form 25-NSE filed by Theratechnologies Inc.25-NSE - Theratechnologies Inc. (0001512717) (Subject)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- PRTheratechnologies Announces Completion of Acquisition by Future PakMONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today the completion of the previously-announced plan of arrangement under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"), pursuant to which the Purchaser has acquired all the issued and outstanding common shares of the Company (the "Shares") for US$3.01 per Share in cash plus one contingent value right ("CVR") per Share for additional aggregate cash payments of up to US$1.19 per CVR if
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- PRTheratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future PakMONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). This final court approval follows the approval of the Arrangement by the shareholders of the Company at the special meeting of shareholders held on Septe
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- PRTheratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakMONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). At the special meeting of shareholders of Theratechnologies held earlier today, the arrangement resolution was approved by 97.44% of the votes cast by the holders of shares present in person or virtually or represented by
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- PRTheratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and LipodystrophyEGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV® Specialty pharmacies are now ordering EGRIFTA WR™ to fill prescriptions MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the availability of EGRIFTA WR™ (tesamorelin) for injection for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. The announcement follows the approval of EGRIFTA WR™ by the U.S. Food and Drug Administration (FDA) earlier this year. "Excess visceral abdominal fat is an increasin
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- PRTheratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote "FOR" the Proposed Plan of Arrangement with Future PakYour vote is important regardless of the number of Shares you own.Board unanimously recommends shareholders vote "FOR" the Arrangement.Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.Visit www.theratech.com for more information.Questions or require voting assistance? Contact Laurel Hill Advisory Group at 1-877-452-7184 or email assistance@laurelhill.com. MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that two
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- PRTheratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future PakShareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak's initial non-binding proposal.Board unanimously recommends shareholders vote "FOR" the Arrangement.Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.Visit www.theratech.com for more information.Questions or require votin
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.SCHEDULE 13G/A - Theratechnologies Inc. (0001512717) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.SCHEDULE 13G/A - Theratechnologies Inc. (0001512717) (Subject)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- SECSEC Form 6-K filed by Theratechnologies Inc.6-K - Theratechnologies Inc. (0001512717) (Filer)
- PRTheratechnologies Reports Financial Results for the Second Quarter 2025Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing
THTX FAQ
7 questionsWhat does Theratechnologies Inc. do?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the...What is the latest news on THTX?
Quantisnow has not tracked any new filings, ratings or press releases for THTX in the last 30 days. The most recent wire item was published on November 14, 2025.Where does THTX stock trade?
Theratechnologies Inc. (THTX) is listed on NASDAQ.What sector and industry is THTX in?
Theratechnologies Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about THTX?
Across the last 2 analyst actions on Theratechnologies Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Cantor Fitzgerald: Overweight with a $9.00 price target on 2022-11-17. Recent price targets range from $3.00 to $9.00.What companies are similar to THTX?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare THTX side-by-side with any of them on Quantisnow.How can I track THTX on Quantisnow?
Quantisnow aggregates Theratechnologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow THTX to receive live email and push alerts on every new disclosure.